Trinity Biotech plc (NASDAQ:TRIB) Short Interest Up 213.2% in June

Trinity Biotech plc (NASDAQ:TRIB) was the target of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 37,900 shares, a growth of 213.2% from the May 31st total of 12,100 shares. Based on an average daily volume of 40,400 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.5% of the shares of the company are sold short.

Trinity Biotech Price Performance

Shares of TRIB stock traded up $0.13 during trading hours on Friday, reaching $2.21. The stock had a trading volume of 30,244 shares, compared to its average volume of 69,123. The firm has a market capitalization of $16.84 million, a PE ratio of -0.79 and a beta of 1.16. The firm has a 50-day simple moving average of $1.96 and a 200-day simple moving average of $2.15. Trinity Biotech has a twelve month low of $1.49 and a twelve month high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. On average, equities analysts anticipate that Trinity Biotech will post -2.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Trinity Biotech in a research note on Thursday. They set a “buy” rating for the company.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.